A Phase I Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients with Relapsed and Refractory Multiple Myeloma
MonumentTAL-3: 64407564MMY3002: A Phase III Randomized Study Comparing Talquetamab SC in Combination with Daratumumab SC and Pomalidomide Tal-DP or Talquetamab SC in Combination with Daratumumab SC Tal-D versus Daratumumab SC, Pomalidomide and Dexamethasone DPd, in Participants with Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy
A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
A Phase I, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Belantamab Mafodotin Administered in Combination with Standard of Care in Participants with Newly Diagnosed Multiple Myeloma Pro00039777
A Multicentre, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of GSK2857916, Bortezomib, and Dexamethasone Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone in Participants with Relapsed/Refractory Multiple Myeloma
A Phase III, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide CC-92480, Bortezomib And Dexamethasone MEZIVd Versus Pomalidomide, Bortezomib And Dexamethasone PVd In Subjects With Relapsed Or Refractory Multiple Myeloma RRMM: SUCCESSOR-1
A Safety and Efficacy Study of JNJ?68284528 ciltacabtagene autoleucel Out?of?Specification OOS for Commercial Release in Patients with Multiple Myeloma